Basic Information
CV6 Therapeutics was founded in 2013 with the aim of accelerating the development of these novel targeted small-molecule therapies. CV6 Therapeutics' first oncology drug, CV6-168, has completed preclinical development and will enter its first human clinical trial in 2023.
CV6 Therapeutics （NI） Ltd.
Belfast,NorthernIreland,United Kingdom
less than 15 people
January 01, 2013
information@cv6t.com